Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

被引：0
作者：
Ani John
Baiyu Yang
Roma Shah
机构：
[1] Roche Diagnostics,
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Adherence; Biomarker; First-line treatment; Guidelines; Non-small cell lung cancer; Precision medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1552 / 1566
页数：14
相关论文
共 50 条
  • [1] Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data
    John, Ani
    Yang, Baiyu
    Shah, Roma
    ADVANCES IN THERAPY, 2021, 38 (03) : 1552 - 1566
  • [2] Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
    Pelicon, Veronika
    Cufer, Tanja
    Knez, Lea
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
    Galan, Rocio Jimenez
    Prado-Mel, Elena
    de Sotomayor, Maria Alvarez
    Martin, Laila Abdel-Kader
    BIOLOGY-BASEL, 2023, 12 (02):
  • [4] Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada
    Laforty, C.
    Tong, M.
    Sharma, A.
    Kim, Y.
    Devost, N.
    Qadeer, R.
    Navani, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S656 - S657
  • [5] Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
    Waterhouse, David
    Lam, Jenny
    Betts, Keith A.
    Yin, Lei
    Gao, Sophie
    Yuan, Yong
    Hartman, John
    Rao, Sumati
    Lubinga, Solomon
    Stenehjem, David
    LUNG CANCER, 2021, 156 : 41 - 49
  • [6] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu
    Yuan Gao
    Ying Wang
    Cong Zhao
    Zhiyun Zhang
    Baolan Li
    Tongmei Zhang
    BMC Cancer, 22
  • [7] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Liu, Yanxia
    Gao, Yuan
    Wang, Ying
    Zhao, Cong
    Zhang, Zhiyun
    Li, Baolan
    Zhang, Tongmei
    BMC CANCER, 2022, 22 (01)
  • [8] Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
    Pham Van Luan
    Nguyen Dinh Tien
    Nguyen Minh Hai
    Nguyen Dao Tien
    Thi Thi Duyen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [9] Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small cell lung cancer
    Hsu, Grace G.
    MacKay, Eric
    Scheuer, Nicolas
    Ramagopalan, Sreeram, V
    IMMUNOTHERAPY, 2021, 13 (18) : 1453 - 1456
  • [10] First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
    Kim, Y.
    Sun, J.
    Park, K.
    Park, S. E.
    Lee, S.
    Ahn, M.
    Ahn, J. S.
    Lim, S. W.
    Lee, H.
    Cho, J. H.
    Kim, H. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
12345